Precision Medicine in Acute Myeloid Leukemia
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 July 2026 | Viewed by 653
Special Issue Editor
Interests: acute myeloid leukemia; normal and leukemic stem cells; hematopoietic differentiation; cell differentiation therapy; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is a genetically heterogenous disease characterized by the impaired differentiation and increased proliferation of myeloid progenitor/precursor cells. The development of sequencing technologies has allowed tremendous progress in understanding the molecular pathogenesis of AML, thus showing great genetic and clonal heterogeneity and facilitating the identification of genetic alterations that can be targeted by specific pharmacologic agents. This has enabled the development of precision medicines, examples of which include the introduction of small molecules inhibiting FLT3, IDH1/IDH2, BCL-2 and Menin. The clinical studies carried out using these molecules in refractory/relapsed AML patients have shown moderate activity when they are used as single agents, which can be considerably potentiated by drug combination studies.
Evolving precision medicine treatment options for AML are currently in development, and it is important to emphasize the status of these treatments, focusing on the optimal selection of patients suitable for therapies, drug combinations and the stage of disease development.
For this Special Issue of Cancers, we welcome original research studies and review articles that provide an overview of the most recent advances and future challenges in the use of precision medicine in the treatment of AML patients.
Dr. Ugo Testa
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- precision medicine
- molecular targeting
- DNA sequencing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
